

International Biotechnology Trust plc



Carl Harald Janson

The Board of International Biotechnology Trust plc (the "Company") notes that the Company's Manager, SV Life Sciences Managers LLP, has appointed Carl Harald Janson as Investment Manager, who will start with effect from today 2 September 2013. Carl Harald will be supported by Ailsa Craig to run the quoted side of the portfolio, and managing partner Kate Bingham will continue to manage the unquoted side of the portfolio.

Among Carl Harald's many achievements, the outstanding performance of the Carnegie Biotechnology Fund stands out as a key highlight. During his six years and four months as its Principle Fund Manager, Carl Harald was recognised by Bloomberg as the top performing biotech fund manager worldwide (Table 1). During this time period, the Carnegie Biotechnology Fund had a total return of 54% (USD) while the NASDAQ Biotechnology Index returned minus 26% (USD), a relative outperformance of approximately 80% (USD) (Figure 1).

Carl Harald is excited to be focusing on the International Biotechnology Trust portfolio, and looks forward to the challenge of again delivering excellent long term performance in an area he is passionate about.

Carl Harald qualified as a medical doctor in 1981, completed his PhD in 1990 at the Karolinska Institutet, and qualified as Certified European Financial Analyst from the Stockholm School of Economics in 1999. In 1992 he joined Astra Arcus where he held various positions including Director for Preclinical Research and Development. In 1997 Carl Harald began to combine his medical and pharmaceutical industry insights with finance by working as a Senior Financial Analyst for Hagstromer & Qviberg and then Danske Securities.

In 2000 he gained a role as Senior Portfolio Manager and Principal Fund Manager of the Carnegie Biotechnology Fund at Carnegie Investment Bank in Stockholm. Carl Harald responsibilities at Carnegie Investment Bank also included Fund Manager of the Carnegie Medical Fund, and the Carnegie BiotechBridge Fund.

In 2008 Carl Harald was appointed Investment Manager at Karolinska Development in Stockholm, and has served as a member of the board of various Swedish biotechnology companies including Akinion Pharmaceuticals, Axelar, Aprea, Oncopeptides, and Clanotech. Since 2012 he held various Chief Executive roles for the Karolinska Development portfolio companies.

Figure 1 Bloomberg chart depicting the return in USD for the Carnegie Biotechnology Fund, the NASDAQ Biotechnology Index, and the Russell 2000 Growth Biotech index.




Table 1: Bloomberg based performance ranking.

The ranked performance at various time periods up until March 30, 2007, of funds investing in public biopharmaceutical companies globally. The Carnegie Biotechnology Fund was ranked number 1 over the six years and four months period when Carl Harald Janson was the sole fund manager, as well as at various shorter time periods up until March 30, 2007.

	From Nov 30 2000 to March 30 2007	5 y	4 y	3 y	2 y	1 y	3 months
Carnegie Biotechnology Fund	1	1	1	7	1	1	4
ASPA Stock Biotech	2	3	6	2	10	34	34
Pictet Biotechnology	3	2	4	9	8	6	25
SEB Concept Biotechnology	4	4	3	1	2	4	7
BSO Bio Sante	5	5	22	4	16	5	12
ING Invest - Biotechnology	6	6	13	6	5	9	10
CP Global BioPharma Invest	7	8	10	8	13	20	39
Clariden Biotechnology Equity Fund	8	12	14	14	17	25	26
Dexia Equities L - Biotechnology	9	10	8	10	4	8	11
Nordea I SICAV Biotech Fund	10	9	12	11	24	24	21
Deka-BioTech	11	13	12	15	21	18	16
Franklin Biotechnology Fund	12	17	18	19	23	21	23
Franklin Biotechnology Discovery Fund	13	18	23	22	26	23	24
Altamira Biotechnology Fund	14	24	33	26	32	28	19
OP Topic Biotechnology	15	19	16	18	14	14	14
Credit Suisse Equity Fund	16	33	27	32	28	37	37
BB Biotech	17	16	5	3	3	2	1
Danske Fund - Global Biotech	18	14	9	5	9	10	18
FORTIS L Fund - Equity Biotechnology	19	15	11	21	25	34	29
Danske Invest Bioteknologi Fund	20	11	7	5	7	7	13
Fidelity Select Biotechnology Portfolio	21	20	29	24	24	30	36
Daiwa SB Global Biotechnology Fund B	22	22	24	37	37	36	6
Pictet Biotech Fund - Genome	23	19	19	28	35	19	25
Mercure Biotech	24	23	17	20	18	13	3
CiF Neptune Global Health Fund	25	36	40	39	34	11	2
Rydex Series Biotechnology Fund	25	31	31	27	30	32	28
Allianz RCM Biotechnology Fund	27	29	35	35	39	35	35
KBC Equity Fund - Biotechnology	28	30	32	33	38	31	30
CI Global Biotechnology Corporate Class	29	37	28	34	29	26	9
ProFunds Biotechnology UltraSector	30	25	15	16	19	40	40
Oyster Funds - Oncology	31	27	26	29	22	15	15
DWS Zuerich Bio Science	32	40	37	38	33	22	33
cominvest Fund - biotech	33	21	25	25	20	12	5
UBS Equity Fund	24	38	34	30	27	29	20
Capital Invest biotech Stock	35	35	38	36	36	38	27
Daiwa SB Global Biotechnology Fund	36	28	36	37	37	36	8
DWS Biotech-Aktien Typ 0	37	39	39	40	40	33	38
RH&F Global Life Science Fund	38	34	20	13	12	17	22
ABM AMRO Biotech Fund	39	32	30	31	31	39	32
BankInvest bioteknologi Fund	40	26	21	23	6	3	17

Source: Bloomberg